Single and Multiple Ascending Dose Study of AMG 133 in Participants With Obesity

Summary

The study aims to assess the safety and tolerability of maridebart cafraglutide as single and multiple doses in participants with obesity

Timeline

Start

2020-08-07

Primary completion

2022-11-18

Completion

2022-11-18

Publications

• Background Veniant MM, Lu SC, Atangan L, Komorowski R, Stanislaus S, Cheng Y, Wu B, Falsey JR, Hager T, Thomas VA, Ambhaikar M, Sharpsten L, Zhu Y, Kurra V, Jeswani R, Oberoi RK, Parnes JR, Honarpour N, Neutel J, Strande JL. A GIPR antagonist conjugated to GLP-1 analogues promotes weight loss with improved metabolic parameters in preclinical and phase 1 settings. Nat Metab. 2024 Feb;6(2):290-303. doi: 10.1038/s42255-023-00966-w. Epub 2024 Feb 5.

Drugs

Indications